{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T10:32:20Z","timestamp":1688985140079},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00482-021-00613-x","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:22:57Z","timestamp":1642497777000},"page":"59-72","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CGRP-Antik\u00f6rper in der Migr\u00e4neprophylaxe"],"prefix":"10.1007","volume":"36","author":[{"given":"Till","family":"Hamann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Rimmele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim Patrick","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"613_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-25521-2_5","volume-title":"Erfolgreich gegen Kopfschmerzen und Migr\u00e4ne","author":"H G\u00f6bel","year":"2012","unstructured":"G\u00f6bel\u00a0H (2012) Migr\u00e4ne. In: Erfolgreich gegen Kopfschmerzen und Migr\u00e4ne. Springer, Berlin, Heidelberg, S\u00a055\u2013232"},{"key":"613_CR2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby\u00a0PJ, Edvinsson\u00a0L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48\u201356","journal-title":"Ann Neurol"},{"key":"613_CR3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(97)80021-9","volume":"349","author":"LH Lassen","year":"1997","unstructured":"Lassen\u00a0LH, Ashina\u00a0M (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401\u2013402","journal-title":"Lancet"},{"key":"613_CR4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"V Jonas","year":"1982","unstructured":"Jonas\u00a0V, Lin\u00a0CR, Kawashima\u00a0E, Semon\u00a0D, Swanson\u00a0LW, Mermod\u00a0JJ, Evans\u00a0RM, Rosenfeld\u00a0MG (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240\u2013244","journal-title":"Nature"},{"key":"613_CR5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0165-6147(00)01555-8","volume":"21","author":"C Juaneda","year":"2000","unstructured":"Juaneda\u00a0C, Dumont\u00a0Y, Quirion\u00a0R (2000) The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci 21:432\u2013438","journal-title":"Trends Pharmacol Sci"},{"key":"613_CR6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1749-6632.1992.tb22766.x","volume":"657","author":"C Sternini","year":"1992","unstructured":"Sternini\u00a0C (1992) Enteric and visceral afferent CGRP neurons: targets of innervation and differential expression patterns. Ann NY Acad Sci 657:170\u2013186","journal-title":"Ann NY Acad Sci"},{"issue":"1-3","key":"613_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejphar.2004.07.035","volume":"500","author":"U Arulmani","year":"2004","unstructured":"Arulmani\u00a0U, Maassenvandenbrink\u00a0A, Villal\u00f3n\u00a0CM, Saxena\u00a0PR (2004) Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 500(1-3):315\u2013330","journal-title":"Eur J Pharmacol"},{"key":"613_CR8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1210\/edrv-17-5-533","volume":"17","author":"SJ Wimalawansa","year":"1996","unstructured":"Wimalawansa\u00a0SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17:533\u2013585","journal-title":"Endocr Rev"},{"key":"613_CR9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/jcbfm.1987.126","volume":"7","author":"L Edvinsson","year":"1987","unstructured":"Edvinsson\u00a0L, Ekman\u00a0R, Jansen\u00a0I, McCulloch\u00a0J, Uddman\u00a0R (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J\u00a0Cereb Blood Flow Metab 7:720\u2013728","journal-title":"J Cereb Blood Flow Metab"},{"key":"613_CR10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.2994212","volume":"229","author":"SG Amara","year":"1985","unstructured":"Amara\u00a0SG, Arriza\u00a0JL, Leff\u00a0SE, Swanson\u00a0LW, Evans\u00a0RM, Rosenfeld\u00a0MG (1985) Expression in brain of a\u00a0messenger RNA encoding a\u00a0novel neuropeptide homologous to calcitonin gene-related peptide. Science 229:1094\u20131097","journal-title":"Science"},{"key":"613_CR11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1468-2982.1996.1605310.x","volume":"16","author":"I Jansen-Olesen","year":"1996","unstructured":"Jansen-Olesen\u00a0I, Mortensen\u00a0A, Edvinsson\u00a0L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310\u2013316","journal-title":"Cephalalgia"},{"key":"613_CR12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1526-4610.2007.00854.x","volume":"47","author":"S Thalakoti","year":"2007","unstructured":"Thalakoti\u00a0S, Patil\u00a0VV, Damodaram\u00a0S, Vause\u00a0CV, Langford\u00a0LE, Freeman\u00a0SE, Durham\u00a0PL (2007) Neuron\u2013glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008\u20131023","journal-title":"Headache"},{"key":"613_CR13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1471-4159.2009.06154.x","volume":"110","author":"CV Vause","year":"2009","unstructured":"Vause\u00a0CV, Durham\u00a0PL (2009) CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J\u00a0Neurochem 110:811\u2013821","journal-title":"J Neurochem"},{"issue":"6","key":"613_CR14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/acn3.197","volume":"2","author":"CS Walker","year":"2015","unstructured":"Walker\u00a0CS, Eftekhari\u00a0S, Bower\u00a0RL, Wilderman\u00a0A, Insel\u00a0PA, Edvinsson\u00a0L, Waldvogel\u00a0HJ, Jamaluddin\u00a0MA, Russo\u00a0AF, Hay\u00a0DL (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2(6):595\u2013608","journal-title":"Ann Clin Transl Neurol"},{"key":"613_CR15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo\u00a0AF (2015) Calcitonin gene-related peptide (CGRP): a\u00a0new target for migraine. Annu Rev Pharmacol Toxicol 55:533\u2013552","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"613_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni\u00a0V, Giani\u00a0L, Al-Hassany\u00a0L, Asioli\u00a0GM, Butera\u00a0C, de Boer\u00a0I, Guglielmetti\u00a0M et al (2019) CGRP and migraine from a\u00a0cardiovascular point of view: what do we expect from blocking CGRP? J\u00a0Headache Pain 20:27. https:\/\/doi.org\/10.1186\/s10194-019-0979-y","journal-title":"J Headache Pain"},{"key":"613_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby\u00a0PJ, Lipton\u00a0RB, Ferrari\u00a0MD (2002) Migraine\u2014current understanding and treatment. N\u00a0Engl J Med 346:257\u2013270","journal-title":"N Engl J Med"},{"key":"613_CR18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/1615-1003(200209)31:5<458::AID-PAUZ458>3.0.CO;2-G","volume":"31","author":"V Limmroth","year":"2002","unstructured":"Limmroth\u00a0V (2002) How do sumatriptan and co. work? The action mechanisms of triptans. Pharm Unserer Zeit 31:458","journal-title":"Pharm Unserer Zeit"},{"issue":"6","key":"613_CR19","first-page":"e8711","volume":"12","author":"H Pervez","year":"2020","unstructured":"Pervez\u00a0H, Khemani\u00a0L, Khan\u00a0MA, Seedat\u00a0AM, Roshan\u00a0F (2020) Calcitonin gene-related peptide antagonists as a savior in episodic and chronic migraine: a review. Cureus 12(6):e8711","journal-title":"Cureus"},{"key":"613_CR20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s42451-020-00163-z","volume":"3","author":"H-C Diener","year":"2020","unstructured":"Diener\u00a0H\u2011C, F\u00f6rderreuther\u00a0S, Gaul\u00a0C, Giese\u00a0F, Hamann\u00a0T, Holle-Lee\u00a0D, J\u00fcrgens\u00a0TP, Kamm\u00a0K, Kraya\u00a0T, Lampl\u00a0C (2020) Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor, Erg\u00e4nzung der S1-Leitlinie Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. DGNeurologie 3:124\u2013128","journal-title":"DGNeurologie"},{"key":"613_CR21","series-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","volume-title":"Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor, Erg\u00e4nzung der S1-Leitlinie Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne","author":"H-C Diener","year":"2019","unstructured":"Diener\u00a0H\u2011C, May\u00a0A et al (2019) Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor, Erg\u00e4nzung der S1-Leitlinie Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft f\u00fcr Neurologie, (Online: www.dgn.org\/leitlinien)"},{"key":"613_CR22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby\u00a0PJ, Reuter\u00a0U, Hallstr\u00f6m\u00a0Y, Broessner\u00a0G, Bonner\u00a0JH, Zhang\u00a0F, Sapra\u00a0S, Picard\u00a0H, Mikol\u00a0DD, Lenz\u00a0RA (2017) A controlled trial of erenumab for episodic migraine. N\u00a0Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"613_CR23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick\u00a0DW, Ashina\u00a0M, Brandes\u00a0JL, Kudrow\u00a0D, Lanteri-Minet\u00a0M, Osipova\u00a0V, Palmer\u00a0K, Picard\u00a0H, Mikol\u00a0DD, Lenz\u00a0RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037","journal-title":"Cephalalgia"},{"key":"613_CR24","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick\u00a0DW, Silberstein\u00a0SD, Bigal\u00a0ME, Yeung\u00a0PP, Goadsby\u00a0PJ, Blankenbiller\u00a0T, Grozinski-Wolff\u00a0M, Yang\u00a0R, Ma\u00a0Y, Aycardi\u00a0E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:1999\u20132008","journal-title":"JAMA"},{"issue":"9","key":"613_CR25","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer\u00a0VL, Dodick\u00a0DW, Zhang\u00a0Q, Carter\u00a0JN, Ailani\u00a0J, Conley\u00a0RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE\u20111 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"613_CR26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski\u00a0V, Matharu\u00a0M, Millen\u00a0BA, Ossipov\u00a0MH, Kim\u00a0BK, Yang\u00a0JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE\u20112 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"key":"613_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina\u00a0M, Saper\u00a0J, Cady\u00a0R, Schaeffler\u00a0BA, Biondi\u00a0DM, Hirman\u00a0J, Pederson\u00a0S, Allan\u00a0B, Smith\u00a0J (2020) Eptinezumab in episodic migraine: a\u00a0randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:241\u2013254","journal-title":"Cephalalgia"},{"issue":"6","key":"613_CR28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper\u00a0S, Ashina\u00a0M, Reuter\u00a0U, Brandes\u00a0JL, Dole\u017eil\u00a0D, Silberstein\u00a0S, Winner\u00a0P, Leonardi\u00a0D, Mikol\u00a0D, Lenz\u00a0R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"key":"613_CR29","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke\u00a0HC, Goadsby\u00a0PJ, Shufang\u00a0W, Friedman\u00a0DI, Selzler\u00a0KJ, Aurora\u00a0SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211\u2013e2221","journal-title":"Neurology"},{"key":"613_CR30","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton\u00a0RB, Goadsby\u00a0PJ, Smith\u00a0J, Schaeffler\u00a0BA, Biondi\u00a0DM, Hirman\u00a0J, Pederson\u00a0S, Allan\u00a0B, Cady\u00a0R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE\u20112. Neurology 94:e1365\u2013e1377","journal-title":"Neurology"},{"key":"613_CR31","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper\u00a0SJ, Diener\u00a0HC, Ashina\u00a0M, Brandes\u00a0JL, Friedman\u00a0DI, Reuter\u00a0U, Cheng\u00a0S, Nilsen\u00a0J, Leonardi\u00a0DK, Lenz\u00a0RA, Mikol\u00a0DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309\u2013e2320","journal-title":"Neurology"},{"key":"613_CR32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","volume":"41","author":"DW Dodick","year":"2021","unstructured":"Dodick\u00a0DW, Doty\u00a0EG, Aurora\u00a0SK, Ruff\u00a0DD, Stauffer\u00a0VL, Jedynak\u00a0J, Dong\u00a0Y, Pearlman\u00a0EM (2021) Medication overuse in a\u00a0subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41:340\u2013352","journal-title":"Cephalalgia"},{"issue":"1","key":"613_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener\u00a0HC, Marmura\u00a0MJ, Tepper\u00a0SJ, Cowan\u00a0R, Starling\u00a0AJ, Diamond\u00a0ML, Hirman\u00a0J, Mehta\u00a0L, Brevig\u00a0T, Sperling\u00a0B, Cady\u00a0R (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE\u20112. Headache 61(1):125\u2013136","journal-title":"Headache"},{"issue":"1","key":"613_CR34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein\u00a0SD, Cohen\u00a0JM, Seminerio\u00a0MJ, Yang\u00a0R, Ashina\u00a0S, Katsarava\u00a0Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J\u00a0Headache Pain 21(1):114","journal-title":"J Headache Pain"},{"issue":"1","key":"613_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri\u00a0F, Altamura\u00a0C, Brunelli\u00a0N, Costa\u00a0CM, Aurilia\u00a0C, Egeo\u00a0G, Fofi\u00a0L, Favoni\u00a0V, Pierangeli\u00a0G, Lovati\u00a0C, Aguggia\u00a0M, d\u2019Onofrio\u00a0F, Doretti\u00a0A, Di Fiore\u00a0P, Finocchi\u00a0C, Rao\u00a0R, Bono\u00a0F, Ranieri\u00a0A, Albanese\u00a0M, Cevoli\u00a0S, Barbanti\u00a0P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J\u00a0Headache Pain 22(1):35","journal-title":"J Headache Pain"},{"issue":"10","key":"613_CR36","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners\u00a0WM, Kim\u00a0BK, L\u00e1inez\u00a0MJA, Lanteri-Minet\u00a0M, Pozo-Rosich\u00a0P, Wang\u00a0S, Tockhorn-Heidenreich\u00a0A, Aurora\u00a0SK, Nichols\u00a0RM, Yunes-Medina\u00a0L, Detke\u00a0HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"issue":"10203","key":"613_CR37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari\u00a0MD, Diener\u00a0HC, Ning\u00a0X, Galic\u00a0M, Cohen\u00a0JM, Yang\u00a0R, Mueller\u00a0M, Ahn\u00a0AH, Schwartz\u00a0YC, Grozinski-Wolff\u00a0M, Janka\u00a0L, Ashina\u00a0M (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"key":"613_CR38","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter\u00a0U, Goadsby\u00a0PJ, Lanteri-Minet\u00a0M, Shihua\u00a0W, Hours-Zesiger\u00a0P, Ferrari\u00a0MD, Klatt\u00a0J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a\u00a0randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287","journal-title":"Lancet"},{"issue":"6","key":"613_CR39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper\u00a0SJ, Ashina\u00a0M, Reuter\u00a0U, Brandes\u00a0JL, Dole\u017eil\u00a0D, Silberstein\u00a0SD, Winner\u00a0P, Zhang\u00a0F, Cheng\u00a0S, Mikol\u00a0DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40(6):543\u2013553","journal-title":"Cephalalgia"},{"issue":"1","key":"613_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco\u00a0S, Bendtsen\u00a0L, Ashina\u00a0M, Reuter\u00a0U, Terwindt\u00a0G, Mitsikostas\u00a0DD, Martelletti\u00a0P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J\u00a0Headache Pain 20(1):6","journal-title":"J Headache Pain"},{"key":"613_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello\u00a0R, Tiseo\u00a0C, Frattale\u00a0I, Perrotta\u00a0G, Marini\u00a0C, Pistoia\u00a0F, Sacco\u00a0S (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J\u00a0Headache Pain 20:99","journal-title":"J Headache Pain"},{"key":"613_CR42","volume-title":"Informationen der DMKG zum Einsatz monoklonaler Antik\u00f6rper in der Migr\u00e4neprophylaxe","author":"DMKG","year":"2018","unstructured":"DMKG (2018) Informationen der DMKG zum Einsatz monoklonaler Antik\u00f6rper in der Migr\u00e4neprophylaxe"},{"issue":"1","key":"613_CR43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt\u00a0T, Reuter\u00a0U, Tepper\u00a0S, Ashina\u00a0M, Kudrow\u00a0D, Broessner\u00a0G, Boudreau\u00a0GP, McAllister\u00a0P, Vu\u00a0T, Zhang\u00a0F, Cheng\u00a0S, Picard\u00a0H, Wen\u00a0S, Kahn\u00a0J, Klatt\u00a0J, Mikol\u00a0D (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J\u00a0Headache Pain 19(1):92","journal-title":"J Headache Pain"},{"key":"613_CR44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s10194-021-01230-w","volume":"22","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt\u00a0TJ, Kuruppu\u00a0DK, Dong\u00a0Y, Standley\u00a0K, Yunes-Medina\u00a0L, Pearlman\u00a0E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J\u00a0Headache Pain 22:15","journal-title":"J Headache Pain"},{"issue":"10","key":"613_CR45","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/head.13654","volume":"59","author":"PK Winner","year":"2019","unstructured":"Winner\u00a0PK, Spierings\u00a0ELH, Yeung\u00a0PP, Aycardi\u00a0E, Blankenbiller\u00a0T, Grozinski-Wolff\u00a0M, Yang\u00a0R, Ma\u00a0Y (2019) Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59(10):1743\u20131752","journal-title":"Headache"},{"issue":"23","key":"613_CR46","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner\u00a0PK, McAllister\u00a0P, Chakhava\u00a0G, Ailani\u00a0J, Ettrup\u00a0A, Krog Josiassen\u00a0M, Lindsten\u00a0A, Mehta\u00a0L, Cady\u00a0R (2021) Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 325(23):2348\u20132356","journal-title":"JAMA"},{"issue":"Suppl 1","key":"613_CR47","first-page":"P0328","volume":"22","author":"LH Overeem","year":"2021","unstructured":"Overeem\u00a0LH, Peikert\u00a0A, Hofacker\u00a0MD, Kamm\u00a0K, Ruscheweyh\u00a0R, Gandolla\u00a0A, Raffaelli\u00a0B, Reuter\u00a0U, Neeb\u00a0L (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. J\u00a0Headache Pain 22(Suppl 1):P328 (The International Headache Congress\u2014IHS and EHF Joint Congress 2021)","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"613_CR48","first-page":"P0291","volume":"22","author":"N Moroll\u00f3n","year":"2021","unstructured":"Moroll\u00f3n\u00a0N, Belv\u00eds\u00a0R, De Dios\u00a0A, Pag\u00e8s\u00a0A, Massip\u00a0M (2021) What if a\u00a0monoclonal antibody doesn\u2019t work as a\u00a0migraine preventive treatment? Description of the experience in switching between monoclonals antibodies in a\u00a0Headache Unit. J\u00a0Headache Pain 22(Suppl 1):P291 (The International Headache Congress\u2014IHS and EHF Joint Congress 2021)","journal-title":"J Headache Pain"},{"key":"613_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211046617","author":"B Raffaelli","year":"2021","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Overeem\u00a0LH, Mecklenburg\u00a0J, Neeb\u00a0L, Steinicke\u00a0M, Reuter\u00a0U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a\u00a0prospective, longitudinal cohort study. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"key":"613_CR50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer\u00a0VL, Shufang\u00a0W, Voulgaropoulos\u00a0M, Skljarevski\u00a0V, Kovacik\u00a0A, Aurora\u00a0SK (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59:834\u2013847","journal-title":"Headache"},{"issue":"Suppl 1","key":"613_CR51","first-page":"P0287","volume":"22","author":"B Raffaelli","year":"2021","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Overeem\u00a0LH, Mecklenburg\u00a0J, Neeb\u00a0L, Reuter\u00a0U (2021) Migraine evolution after discontinuation of preventive treatment with CGPR-(receptor) antibodies: a\u00a0prospective, longitudinal study. J\u00a0Headache Pain 22(Suppl 1):P287 (The International Headache Congress\u2014IHS and EHF Joint Congress 2021)","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"613_CR52","first-page":"P0302","volume":"22","author":"G Vaghi","year":"2021","unstructured":"Vaghi\u00a0G, Bitetto\u00a0V, Guaschino\u00a0E, De Icco\u00a0R, Ghiotto\u00a0N, Tassorelli\u00a0C, Sances\u00a0G (2021) Does erenumab suspension affect chronic migraine course? A real life experience. J\u00a0Headache Pain 22(Suppl 1):P302 (The International Headache Congress\u2014IHS and EHF Joint Congress 2021)","journal-title":"J Headache Pain"},{"key":"613_CR53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0333102420970507","volume":"41","author":"A Melo-Carrillo","year":"2021","unstructured":"Melo-Carrillo\u00a0A, Strassman\u00a0AM, Schain\u00a0AJ, Manack Adams\u00a0A, Brin\u00a0MF, Burstein\u00a0R (2021) Combined onabotulinumtoxin A\/atogepant treatment blocks activation\/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia 41:17\u201332","journal-title":"Cephalalgia"},{"issue":"2","key":"613_CR54","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld\u00a0AM, Frishberg\u00a0BM, Schim\u00a0JD, Iannone\u00a0A, Schneider\u00a0G, Yedigarova\u00a0L, Manack Adams\u00a0A (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxin A: a retrospective chart review. Pain Ther 10(2):809\u2013826","journal-title":"Pain Ther"},{"issue":"1","key":"613_CR55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s10194-020-01211-5","volume":"22","author":"JM Cohen","year":"2021","unstructured":"Cohen\u00a0JM, Ning\u00a0X, Kessler\u00a0Y, Rasamoelisolo\u00a0M, Campos\u00a0VR, Seminerio\u00a0MJ, Krasenbaum\u00a0LJ, Shen\u00a0H, Stratton\u00a0J (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. J\u00a0Headache Pain 22(1):3","journal-title":"J Headache Pain"},{"issue":"5","key":"613_CR56","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina\u00a0M, Goadsby\u00a0PJ, Reuter\u00a0U, Silberstein\u00a0S, Dodick\u00a0DW, Xue\u00a0F, Zhang\u00a0F, Paiva da Silva Lima\u00a0G, Cheng\u00a0S, Mikol\u00a0DD (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5\u2011year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"key":"613_CR57","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/head.13427","volume":"58","author":"N Rosen","year":"2018","unstructured":"Rosen\u00a0N, Pearlman\u00a0E, Ruff\u00a0D, Day\u00a0K, Nagy\u00a0AJ (2018) 100\u202f% response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE\u20111 and EVOLVE-2\u00a0studies. Headache 58:1347\u20131357","journal-title":"Headache"},{"issue":"11-12","key":"613_CR58","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/03331024211017879","volume":"41","author":"V Gonz\u00e1lez-Quintanilla","year":"2021","unstructured":"Gonz\u00e1lez-Quintanilla\u00a0V, P\u00e9rez-Pereda\u00a0S, Gonz\u00e1lez-Su\u00e1rez\u00a0A, Madera\u00a0J, Toriello\u00a0M, Pascual\u00a0J (2021) Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: a report of two cases. Cephalalgia 41(11-12):1272\u20131275","journal-title":"Cephalalgia"},{"key":"613_CR59","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00482-020-00500-x","volume":"34","author":"T Hamann","year":"2020","unstructured":"Hamann\u00a0T, Kamm\u00a0K, Kropp\u00a0P, Rimmele\u00a0F, J\u00fcrgens\u00a0TP (2020) Migr\u00e4neprophylaxe \u2013 alles nur noch Antik\u00f6rper? Schmerz 34:476\u2013485. https:\/\/doi.org\/10.1007\/s00482-020-00500-x","journal-title":"Schmerz"},{"issue":"4","key":"613_CR60","doi-asserted-by":"crossref","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen\u00a0ID, Brumfiel\u00a0CM, Patel\u00a0MH, Butterfield\u00a0RJ, VanderPluym\u00a0JH, Griffing\u00a0L, Pittelkow\u00a0MR, Mangold\u00a0AR (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4(4):e217934","journal-title":"JAMA Netw Open"},{"key":"613_CR61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pediatrneurol.2020.09.014","volume":"114","author":"KA Greene","year":"2021","unstructured":"Greene\u00a0KA, Gentile\u00a0CP, Szperka\u00a0CL, Yonker\u00a0M, Gelfand\u00a0AA, Grimes\u00a0B, Irwin\u00a0SL (2021) Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol 114:62\u201367","journal-title":"Pediatr Neurol"},{"key":"613_CR62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda\u00a0R, Bedussi\u00a0F, Gobbi\u00a0C, Zecca\u00a0C, Ceschi\u00a0A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41:789\u2013798","journal-title":"Cephalalgia"},{"issue":"11-12","key":"613_CR63","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/03331024211018137","volume":"41","author":"F Frank","year":"2021","unstructured":"Frank\u00a0F, Ulmer\u00a0H, Sidoroff\u00a0V, Broessner\u00a0G (2021) CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia 41(11-12):1222\u20131239","journal-title":"Cephalalgia"},{"key":"613_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571","author":"U Reuter","year":"2021","unstructured":"Reuter\u00a0U, Ehrlich\u00a0M, Gendolla\u00a0A, Heinze\u00a0A, Klatt\u00a0J, Wen\u00a0S, Hours-Zesiger\u00a0P, Nickisch\u00a0J, Sieder\u00a0C, Hentschke\u00a0C, Maier-Peuschel\u00a0M (2021) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"613_CR65","volume-title":"Novartis announces positive results from a\u00a0Phase IV study showing superior tolerability and efficacy of Aimovig\u00ae (erenumab) compared with topiramate in migraine prevention","author":"Novartis","year":"2020","unstructured":"Novartis (2020) Novartis announces positive results from a\u00a0Phase IV study showing superior tolerability and efficacy of Aimovig\u00ae (erenumab) compared with topiramate in migraine prevention. Novartis, Basel"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-021-00613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-021-00613-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-021-00613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T08:07:06Z","timestamp":1644480426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-021-00613-x"}},"subtitle":["Der neue Standard in der Migr\u00e4netherapie?"],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s00482-021-00613-x","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"27 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>T.\u00a0Hamann<\/b>: A.\u00a0Finanzielle Interessen: T.\u00a0Hamann gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Assistenzart, Klinik und Poliklinik f\u00fcr Neurologie, Kopfschmerzzentrum Nord-Ost, Universit\u00e4tsmedizin Rostock | Mitgliedschaften: Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG), Deutsche Gesellschaft f\u00fcr Neurologie (DGN), Hartmannbund, Marburger Bund. <b>F.\u00a0Rimmele<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Innovationsfonds des Gemeinsamen Bundesausschusses: Interventionsstudie (Personal), Teva: klinische Studie (Personal), Novartis: klinische Studie (Personal), Chordate: klinische Studie (Personal), Lilly: klinische Studie (Personal), Europ\u00e4ischer Fonds f\u00fcr regionale Entwicklung (EFRE): Ger\u00e4te.\u00a0\u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Allergan, Novartis, Teva, Lilly, Ipsen, Merz, Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG): Kostenerstattung f\u00fcr Reise\u2011, \u00dcbernachtungs\u2011, Teilnahmegeb\u00fchren sowie Sprecherhonorare; Autorenhonorare: Elsevier. \u2013\u00a0Beratert\u00e4tigkeit (\u201eadvisory board\u201c): Novartis, Teva, Allergan\/AbbVie.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Facharzt f\u00fcr Neurologie, Klinik und Poliklinik f\u00fcr Neurologie, Universit\u00e4tsmedizin Rostock, Rostock | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie (DGN), Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG), Marburger Bund. <b>T.P.\u00a0J\u00fcrgens<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung vom Innovationsfonds des Gemeinsamen Bundesausschusses (Personal), des Europ\u00e4ischer Fonds f\u00fcr regionale Entwicklung (EFRE) (Ger\u00e4te) sowie der Firma Novartis (Personal). \u2013\u00a0Honorare f\u00fcr Vortr\u00e4ge von Allergan, Hormosan, Lilly, Novartis, Sanofi-Aventis und Teva.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Allergan, Hormosan, Lilly, Lundbeck, Novartis und Teva. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Chefarzt, Neurologisches Zentrum, Klinik f\u00fcr Neurologie, KMG Klinikum G\u00fcstrow, Mitglied und Pr\u00e4sident der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft, Associate Editor: <i>Frontiers of Neurology\u00a0\u2013 Headache and Neurogenic Pain<\/i>; Mitglied Editorial Board: <i>Journal of Headache and Pain<\/i>. | Mitgliedschaften: Deutsche Schmerzgesellschaft, Deutsche Gesellschaft f\u00fcr Neurologie, Gesellschaft f\u00fcr Nervenheilkunde Mecklenburg-Vorpommern, Deutsche Multiple Sklerose Gesellschaft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}